R. Angelo
de Claro
M. D.
Leadership Role
Acting
Director - Oncology Center of Excellence
Dr. Angelo de Claro is the Acting Director of the FDA’s Oncology Center of Excellence (OCE), leading the center’s efforts to develop and execute an integrated regulatory approach that enhances the cross-center coordination of oncology product clinical review. OCE was established in 2017 to leverage the combined skills of the FDA’s regulatory scientists and reviewers with expertise in drugs, biologics, and devices to expedite the development of novel cancer products.
He began his government career with the FDA Office of Hematology and Oncology Products, Division of Hematology Products as a Medical Officer in 2010, was promoted to Medical Officer team leader in 2012, followed by promotion to Division Director in Office of Oncologic Diseases (OOD) in 2019. Since March 2025, he has held dual roles as Deputy Office Director for OOD and Deputy Center Director for the Oncology Center of Excellence.
Dr. de Claro has made significant contributions to programs across OCE and OOD. He has led OCE’s global clinical sciences program since 2019, including coordination for Project Orbis, an OCE program to facilitate the submission and review of oncology marketing applications across several partner regulatory agencies. He has provided leadership for the oncology cluster and bilateral meetings with Australia, Brazil, Canada, European Union, Israel, Japan, Singapore, Switzerland, and the United Kingdom. In addition, he was instrumental in the launch of the Real-Time Oncology Review (RTOR) program.
Dr. de Claro received his B.S. in Basic Medical Sciences (magna cum laude) and his M.D. (magna cum laude) from the University of the Philippines. He completed his internal medicine residency at Baylor College of Medicine in Houston, Texas and hematology-oncology fellowship at University of Washington in Seattle. He then joined the hematology-oncology faculty at University of Washington/Harborview Medical Center. He is an expert in his field and has published widely, with more than 60 peer reviewed articles.